CAPR — Recent News Coverage
All news mentioning CAPR in ESEN's AI-graded feed
News stories with CAPR as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on CAPR. See /coverage/CAPR for the 30-day aggregate.
FINANCIALPOST.COM
·
2026-08-14
LOW
BEARISH
CORR0.15
Kaplan Fox Announces a Securities Class Action Filed Against Capricor Therapeutics, Inc. (NASDAQ: CAPR) – Lead Plaintiff Deadline is September 28, 2026
$CAPR
◈ ESEN AI
CAPR faces a securities class action lawsuit filed by Kaplan Fox, a litigation firm specializing in shareholder disputes. The lead plaintiff deadline is set for September 28, 2026, suggesting the lawsuit is in early sta…
RTTNEWS.COM
·
2026-08-14
LOW
NEUTRAL
CORR0.15
Morning Market Movers: WETO, CAPR, AKAN, DAAQ See Big Swings
$WETO
$CAPR
$AKAN
$DAAQ
◈ ESEN AI
This premarket note catalogs early trading activity in four micro-cap or lower-liquidity securities without identifying fundamental catalysts or material company-specific developments. The mention of "big swings" and "n…
FINANCIALPOST.COM
·
2026-08-12
LOW
BEARISH
CORR-0.15
Kaplan Fox Alerts Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) with Significant Losses to a Securities Class Action Deadline on September 28, 2026
$CAPR
◈ ESEN AI
Capricor Therapeutics (CAPR) faces a securities class action lawsuit with a filing deadline of September 28, 2026, as announced by litigation firm Kaplan Fox. This represents a procedural disclosure typical of disclosed…
FINANCIALPOST.COM
·
2026-08-10
LOW
BEARISH
CORR0.15
Kaplan Fox Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Who Suffered Losses to a Securities Class Action – Deadline is September 28, 2026
$CAPR
◈ ESEN AI
CAPR is subject to a securities class action lawsuit, with Kaplan Fox alerting investors of losses and establishing a September 28, 2026 deadline for claim participation. This represents a procedural disclosure typical …
FINANCIALPOST.COM
·
2026-08-06
LOW
BEARISH
CORR-0.15
Kaplan Fox Reminds Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors with Significant Losses to Seek a Leadership Role Before Deadline on September 28, 2026
$CAPR
◈ ESEN AI
Capricor Therapeutics (CAPR) has experienced significant shareholder losses, prompting legal action notification from law firm Kaplan Fox. This class-action recruitment effort indicates material investor harm, likely st…
RTTNEWS.COM
·
2026-07-30
HIGH
BEARISH
CORR-0.72
Capricor Therapeutics Stock Tanks 54% Over FDA Panel's Negative Vote On Deramiocel Effectiveness
$CAPR
◈ ESEN AI
Capricor Therapeutics (CAPR) experienced a severe single-day collapse following an FDA advisory committee's rejection of clinical efficacy for Deramiocel, its lead candidate targeting cardiomyopathy in Duchenne muscular…
MANILATIMES.NET
·
2026-07-29
NEUTRAL
BULLISH
CORR0.35
The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy
$CAPR
◈ ESEN AI
The Lancet publication of HOPE-3 trial data for Capricor Therapeutics' (CAPR) deramiocel represents a significant validation milestone for the company's rare disease pipeline in Duchenne Muscular Dystrophy (DMD). Indepe…
SEEKINGALPHA.COM
·
2026-07-28
HIGH
BEARISH
CORR0.15
Capricor Therapeutics: Downgrading To Sell As FDA Doubts Mount (NASDAQ:CAPR)
$CAPR
◈ ESEN AI
Capricor Therapeutics (CAPR) faces a significant headwind following a downgrade to Sell, driven by FDA efficacy doubts surrounding its lead candidate deramiocel in Duchenne muscular dystrophy (DMD) cardiomyopathy. This …
SEEKINGALPHA.COM
·
2026-07-28
HIGH
BEARISH
CORR-0.72
Capricor Stock Tanks On FDA AdCom Notes - What Investors Should Know (NASDAQ:CAPR)
$CAPR
◈ ESEN AI
Capricor (CAPR) experienced a sharp 65% equity decline following negative FDA Advisory Committee feedback on deramiocel's efficacy profile for Duchenne Muscular Dystrophy treatment. The FDA's determination that clinical…
MANILATIMES.NET
·
2026-06-26
NEUTRAL
NEUTRAL
CORR0.15
Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
$CAPR
◈ ESEN AI
Capricor Therapeutics (CAPR) has scheduled an FDA Advisory Committee meeting for July 29, 2026, to review a Biologics License Application (BLA) for deramiocel in Duchenne muscular dystrophy treatment. This represents a …
MANILATIMES.NET
·
2026-06-26
HIGH
BULLISH
CORR0.72
Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference
$CAPR
◈ ESEN AI
Capricor Therapeutics (CAPR) announced positive five-year efficacy and safety data for deramiocel in Duchenne muscular dystrophy, a rare, severe genetic disorder. The HOPE-2 Open-Label Extension study demonstrated durab…
EXPLORE OTHER FILTERS